BACKGROUND: Atrial fibrillation (AF) ablation under uninterrupted warfarin use is safe and recommended by experts. However, there is some controversy regarding direct-acting oral anticoagulants for the same purpose. OBJECTIVE: To evaluate the safety of AF ablation under uninterrupted anticoagulation with rivaroxaban. METHODS: A series of 130 patients underwent AF radiofrequency ablation under uninterrupted rivaroxaban use (RIV group) and was compared to a control group of 110 patients under uninterrupted warfarin use (WFR group) and therapeutic International Normalized Ratio (INR). We analyzed death, rates of thromboembolic events, major and minor bleedings, activated clotting time (ACT) levels, and heparin dose in the procedure. The ablation protocol basically consisted of circumferential isolation of the pulmonary veins guided by electroanatomic mapping. It was adopted a statistical significance of 5%. RESULTS: The clinical characteristics of the groups were similar, and the paroxysmal AF was the most frequent type (63% and 59%, RIV and WFR groups). A thromboembolic event occurred in the RIV group. There were 3 patients with major bleeding (RIV = 1 and WFR = 2; p = 0.5); no deaths. Basal INR was higher in the WFR group (2.5 vs. 1.2 ± 0.02; p < 0.0001), with similar basal ACT levels (123.7 ± 3 vs. 118 ± 4; p= 0, 34). A higher dose of venous heparin was used in the RIV group (9,414 ± 199 vs. 6,019 ± 185 IU; p < 0.0001) to maintain similar mean ACT levels during the procedure (350 ± 3 vs. 348.9 ± 4; p = 0.79). CONCLUSION: In the study population, AF ablation under uninterrupted rivaroxaban showed a safety profile that was equivalent to uninterrupted warfarin use with therapeutic INR.
BACKGROUND:Atrial fibrillation (AF) ablation under uninterrupted warfarin use is safe and recommended by experts. However, there is some controversy regarding direct-acting oral anticoagulants for the same purpose. OBJECTIVE: To evaluate the safety of AF ablation under uninterrupted anticoagulation with rivaroxaban. METHODS: A series of 130 patients underwent AF radiofrequency ablation under uninterrupted rivaroxaban use (RIV group) and was compared to a control group of 110 patients under uninterrupted warfarin use (WFR group) and therapeutic International Normalized Ratio (INR). We analyzed death, rates of thromboembolic events, major and minor bleedings, activated clotting time (ACT) levels, and heparin dose in the procedure. The ablation protocol basically consisted of circumferential isolation of the pulmonary veins guided by electroanatomic mapping. It was adopted a statistical significance of 5%. RESULTS: The clinical characteristics of the groups were similar, and the paroxysmal AF was the most frequent type (63% and 59%, RIV and WFR groups). A thromboembolic event occurred in the RIV group. There were 3 patients with major bleeding (RIV = 1 and WFR = 2; p = 0.5); no deaths. Basal INR was higher in the WFR group (2.5 vs. 1.2 ± 0.02; p < 0.0001), with similar basal ACT levels (123.7 ± 3 vs. 118 ± 4; p= 0, 34). A higher dose of venous heparin was used in the RIV group (9,414 ± 199 vs. 6,019 ± 185 IU; p < 0.0001) to maintain similar mean ACT levels during the procedure (350 ± 3 vs. 348.9 ± 4; p = 0.79). CONCLUSION: In the study population, AF ablation under uninterrupted rivaroxaban showed a safety profile that was equivalent to uninterrupted warfarin use with therapeutic INR.
Authors: Hugh Calkins; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Harvey Serota; Matias Nordaby; Kelly Guiver; Branislav Biss; Marc A Brouwer; Massimo Grimaldi Journal: N Engl J Med Date: 2017-03-19 Impact factor: 91.245
Authors: Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber Journal: Heart Rhythm Date: 2012-03-01 Impact factor: 6.343
Authors: Hugh Calkins; Gerhard Hindricks; Riccardo Cappato; Young-Hoon Kim; Eduardo B Saad; Luis Aguinaga; Joseph G Akar; Vinay Badhwar; Josep Brugada; John Camm; Peng-Sheng Chen; Shih-Ann Chen; Mina K Chung; Jens Cosedis Nielsen; Anne B Curtis; D Wyn Davies; John D Day; André d'Avila; N M S Natasja de Groot; Luigi Di Biase; Mattias Duytschaever; James R Edgerton; Kenneth A Ellenbogen; Patrick T Ellinor; Sabine Ernst; Guilherme Fenelon; Edward P Gerstenfeld; David E Haines; Michel Haissaguerre; Robert H Helm; Elaine Hylek; Warren M Jackman; Jose Jalife; Jonathan M Kalman; Josef Kautzner; Hans Kottkamp; Karl Heinz Kuck; Koichiro Kumagai; Richard Lee; Thorsten Lewalter; Bruce D Lindsay; Laurent Macle; Moussa Mansour; Francis E Marchlinski; Gregory F Michaud; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Ken Okumura; Douglas Packer; Evgeny Pokushalov; Matthew R Reynolds; Prashanthan Sanders; Mauricio Scanavacca; Richard Schilling; Claudio Tondo; Hsuan-Ming Tsao; Atul Verma; David J Wilber; Teiichi Yamane Journal: Heart Rhythm Date: 2017-09-15 Impact factor: 6.343
Authors: Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman Journal: Lancet Date: 2013-12-04 Impact factor: 79.321
Authors: Vinit Sawhney; Masooma Shaukat; Elena Volkova; Nicola Jones; Rui Providencia; Shoreh Honarbakhsh; Gurpreet Dhillon; Anthony Chow; Martin Lowe; Pier D Lambiase; Mehul Dhinoja; Simon Sporton; Mark James Earley; Richard John Schilling; Ross Jacob Hunter Journal: Pacing Clin Electrophysiol Date: 2018-05-16 Impact factor: 1.976
Authors: Riccardo Cappato; Francis E Marchlinski; Stefan H Hohnloser; Gerald V Naccarelli; Jim Xiang; David J Wilber; Chang-Sheng Ma; Susanne Hess; Darryl S Wells; George Juang; Johan Vijgen; Burkhard J Hügl; Richard Balasubramaniam; Christian De Chillou; D Wyn Davies; L Eugene Fields; Andrea Natale Journal: Eur Heart J Date: 2015-05-14 Impact factor: 29.983
Authors: Paulus Kirchhof; Karl Georg Haeusler; Benjamin Blank; Joseph De Bono; David Callans; Arif Elvan; Thomas Fetsch; Isabelle C Van Gelder; Philip Gentlesk; Massimo Grimaldi; Jim Hansen; Gerhard Hindricks; Hussein R Al-Khalidi; Tyler Massaro; Lluis Mont; Jens Cosedis Nielsen; Georg Nölker; Jonathan P Piccini; Tom De Potter; Daniel Scherr; Ulrich Schotten; Sakis Themistoclakis; Derick Todd; Johan Vijgen; Luigi Di Biase Journal: Eur Heart J Date: 2018-08-21 Impact factor: 29.983
Authors: Mate Vamos; Riccardo Cappato; Francis E Marchlinski; Andrea Natale; Stefan H Hohnloser Journal: Europace Date: 2016-01-20 Impact factor: 5.214